A Phase 1 double blind, randomized, placebo-controlled trial of HNSA-5487 in healthy male and female adult participants
Latest Information Update: 10 Oct 2024
At a glance
- Drugs HNSA-5487 (Primary)
- Indications Autoimmune disorders; Cancer
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Acronyms NICE-01
- Sponsors Hansa Biopharma AB
Most Recent Events
- 07 Oct 2024 According to a Hansa Biopharma AB media release,positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487 were presented.
- 07 Oct 2024 Results published in the Hansa Biopharma AB Media Release
- 26 Oct 2023 According to a Hansa Biopharma AB media release, Further analysis around endpoints to be completed in 2024 .